One shot to stop HPV spread? new trial tests Vaccine's hidden power

NCT ID NCT07303751

Not yet recruiting Disease control Sponsor: Institut d'Investigació Biomèdica de Bellvitge Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether a single dose of the HPV vaccine (Gardasil-9) can reduce the infectivity of high-risk HPV in women aged 18-29 who already have the virus. Researchers will compare cervical samples from vaccinated and unvaccinated women at 6 months to see if vaccine-induced antibodies neutralize the virus. If successful, it could suggest a new way to control HPV transmission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nonavalent HPV vaccine (Gardasil-9)
What this could lead to: If it works, this could show that a single HPV vaccine dose reduces how easily the virus spreads, potentially lowering infection rates in communities.
What could go wrong: This is a small, early-phase trial with only 80 participants. It measures infectivity in lab samples, not actual transmission, so real-world impact is uncertain. The vaccine may not reduce infectivity as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-RISK HPV (ANY STRAIN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical squamous intraepithelial neoplasia human papilloma virus infection Infections Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH-RISK HPV (ANY STRAIN) HPV HUMAN PAPILLOMAVIRUS (HPV) INFECTIONS

Contacts and locations

Locations

Kambia Research Centre

Freetown, Sierra Leone

More trials for these conditions

Other studies related to the condition(s) this trial covers.